Pre-IPO Beijing Biostar Pharmaceuticals- Core Product Has Obvious Defects; Outlook Is Not Optimistic
Biostar highly relies on Utidelone Injection to generate revenue, but it has obvious defects in front of competitors. Due to fierce competition...
No more insights